

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC.
Petitioners

v.

ALKERMES PHARMA IRELAND LIMITED
Patent Owner

Case No. IPR2025-00514
Patent 7,919,499

**DECLARATION OF THOMAS CHARLES DOWLING, Pharm.D., Ph.D. IN
SUPPORT OF PETITION FOR *INTER PARTES* REVIEW OF U.S.
PATENT NO. 7,919,499**

APOTEX EXHIBIT 1046
Anotex v. Alkermes

TABLE OF CONTENTS

	<u>Page</u>
I. INTRODUCTION	1
II. BACKGROUND AND QUALIFICATIONS	2
III. INFORMATION CONSIDERED	7
IV. RELEVANT LEGAL STANDARDS	7
A. Claim Interpretation	7
B. Perspective of One of Ordinary Skill in the Art.....	7
C. Anticipation	8
D. Obviousness.....	8
V. SUMMARY OF OPINIONs	11
VI. THE CHALLENGED '499 Patent	11
VII. LEVEL OF ORDINARY SKILL IN THE ART	11
VIII. TECHNICAL BACKGROUND	13
A. The Purported Invention.....	13
B. Pertinent Prosecution History Of The '499 Patent.....	18
C. Summary of the Applied Prior Art.....	20
1. Comer (EX1004).....	20
2. Nuwayser (EX1005)	23
3. Rubio (EX1006).....	24
4. Wright (EX1007)	25
5. Kranzler (EX1008).....	25
D. State Of The Art	26

E.	The Area Under the Curve (AUC)	28
F.	AUC Does Not Meaningfully Impact Efficacy.....	31
G.	A POSITA Would Find the Claimed Comparison Inapt	33
H.	The Claimed AUC Differential is Known or Would be Apparent	36
1.	The AUC of Comer.....	36
2.	The AUC of Nuwayser	43
IX.	CLAIM CONSTRUCTION	45
A.	“the step of parenterally administering a long acting formulation comprising about 310 mg to about 480 mg of naltrexone”	45
B.	“the serum AUC of naltrexone ... than that achieved by 50 mg/day oral administration”	46
C.	“about three”.....	48
D.	“five or more days”	49
E.	“initial oral dose”.....	50
F.	“about 35% by weight”	51
X.	THE CHALLENGED CLAIMS ARE ANTICIPATED OR OBVIOUS IN VIEW OF THE PRIOR ART	51
A.	Ground 1: Claims 1, 3-5, and 12 Are Anticipated by Comer	51
1.	Claim 1 (Preamble): A method for treating an individual in need of naltrexone comprising the step of.....	52
a.	[1.1]: parenterally administering a long acting formulation comprising	52
b.	[1.2]: about 310 mg to about 480 mg of naltrexone	54

Declaration of Thomas Charles Dowling, Pharm.D., Ph.D.

c.	[1.3]: and a biocompatible polymer to the individual	55
d.	[1.4]: wherein the serum AUC of naltrexone is about three times greater than that achieved by 50 mg/day oral administration	55
e.	[1.5]: and wherein the biocompatible polymer is a polylactide-co-glycolide polymer.....	57
2.	Claim 3: The method of claim 1 wherein the long acting formulation releases naltrexone for a period of at least two weeks.....	57
3.	Claim 4: The method of claim 1 wherein the long acting formulation releases naltrexone for a period of about four weeks.....	58
4.	Claim 5: The method of claim 1 wherein the long acting formulation is administered in a dose of about 380 mg of naltrexone wherein the serum AUC is about 3.3 times greater than that achieved by 50 mg/day oral administration.....	58
5.	Claim 12: The method of claim 1 wherein naltrexone is administered by injection.....	59
B.	Ground 2: Claims 1-13 Would Have Been Obvious Over Comer in view of Nuwayser, Rubio, and Wright	59
1.	Claim 1	62
2.	Claim 2	66
3.	Claim 3	66
4.	Claim 4	67
5.	Claim 5	67
6.	Claim 6	67
7.	Claims 7-9	68

...

Declaration of Thomas Charles Dowling, Pharm.D., Ph.D.

8.	Claim 10.....	69
9.	Claim 11.....	69
10.	Claim 12.....	70
11.	Claim 13.....	70
C.	Ground 3: Claims 1-13 Would Have Been Obvious Over Nuwayser in View of Comer, Rubio, and Wright.....	71
1.	Claim 1 (Preamble): A method for treating an individual in need of naltrexone comprising the step of.....	71
a.	[1.1]: parenterally administering a long acting formulation comprising	74
b.	[1.2]: about 310 mg to about 480 mg of naltrexone.....	74
c.	[1.3]: and a biocompatible polymer to the individual	77
d.	[1.4]: wherein the serum AUC of naltrexone is about three times greater than that achieved by 50 mg/day oral administration.....	77
e.	[1.5]: and wherein the biocompatible polymer is a polylactide-co-glycolide polymer.....	78
2.	Claim 2.....	78
3.	Claim 3.....	79
4.	Claim 4.....	79
5.	Claim 5.....	79
6.	Claim 6.....	79
7.	Claims 7-9.....	80
8.	Claim 10.....	80
9.	Claim 11.....	80

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.